probucol has been researched along with Liver Steatosis in 10 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the effects of probucol, an agent with strong antioxidant properties, in reversing biochemical changes in nonalcoholic steatohepatitis (NASH)." | 9.10 | Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. ( Ansari, R; Farahvash, MJ; Hormazdi, M; Khatibian, M; Malekzadeh, R; Merat, S; Mikaeli, J; Naserimoghadam, S; Sohrabi, MR; Sotoudehmanesh, R, 2003) |
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 7.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| "Probucol is a lipid-lowering agent with strong antioxidant properties." | 6.71 | Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. ( Malekzadeh, R; Merat, S; Naserimoghadam, S; Rakhshani, N; Sohrabi, MR; Sohrabpour, AA; Sotoudeh, M, 2003) |
| "To evaluate the effects of probucol, an agent with strong antioxidant properties, in reversing biochemical changes in nonalcoholic steatohepatitis (NASH)." | 5.10 | Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study. ( Ansari, R; Farahvash, MJ; Hormazdi, M; Khatibian, M; Malekzadeh, R; Merat, S; Mikaeli, J; Naserimoghadam, S; Sohrabi, MR; Sotoudehmanesh, R, 2003) |
| "We investigated the effect of Probucol in preventing fatty liver in monosodium-L-glutamate (MSG) treated obese mice and control mice fed a high fat diet." | 3.69 | Probucol prevents the progression of fatty liver in MSG obese mice. ( Kondo, M; Sakane, N; Umekawa, T; Yoshida, T; Yoshioka, K, 1995) |
| "Probucol is a lipid-lowering agent with strong antioxidant properties." | 2.71 | Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. ( Malekzadeh, R; Merat, S; Naserimoghadam, S; Rakhshani, N; Sohrabi, MR; Sohrabpour, AA; Sotoudeh, M, 2003) |
| "Non-alcoholic steatohepatitis once considered a benign process is now known to lead to progressive fibrosis and cirrhosis." | 2.43 | Review article: Drug therapy for non-alcoholic fatty liver disease. ( Comar, KM; Sterling, RK, 2006) |
| "Lipid metabolism and steatohepatitis were assessed." | 1.39 | Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets. ( Gao, J; Liu, B; Wu, R; Wu, XL; Xiao, XQ; Zhang, F; Zhang, W; Zhang, X; Zhou, HM, 2013) |
| "Probucol is a lipid-lowering agent with anti-oxidant effects." | 1.35 | Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats. ( Li, Z; Liu, D; Mei, Z; Shen, W; Xu, X; Zhang, X, 2009) |
| "Specific therapy for non-alcoholic steatohepatitis (NASH) is needed because of the potential severity of this liver disease." | 1.35 | Pharmacologic therapy of non-alcoholic steatohepatitis. ( Ratziu, V; Zelber-Sagi, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 8 (80.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, X | 2 |
| Li, Z | 1 |
| Liu, D | 1 |
| Xu, X | 1 |
| Shen, W | 1 |
| Mei, Z | 1 |
| Socha, P | 1 |
| Horvath, A | 1 |
| Vajro, P | 1 |
| Dziechciarz, P | 1 |
| Dhawan, A | 1 |
| Szajewska, H | 1 |
| Ratziu, V | 1 |
| Zelber-Sagi, S | 1 |
| Wu, R | 1 |
| Zhang, W | 1 |
| Liu, B | 1 |
| Gao, J | 1 |
| Xiao, XQ | 1 |
| Zhang, F | 1 |
| Zhou, HM | 1 |
| Wu, XL | 1 |
| Bonkovsky, HL | 1 |
| Merat, S | 3 |
| Malekzadeh, R | 3 |
| Sohrabi, MR | 2 |
| Hormazdi, M | 1 |
| Naserimoghadam, S | 2 |
| Mikaeli, J | 1 |
| Farahvash, MJ | 1 |
| Ansari, R | 1 |
| Sotoudehmanesh, R | 1 |
| Khatibian, M | 1 |
| Sotoudeh, M | 2 |
| Rakhshani, N | 1 |
| Sohrabpour, AA | 1 |
| Comar, KM | 1 |
| Sterling, RK | 1 |
| Aduli, M | 1 |
| Kazemi, R | 1 |
| Sedighi, N | 1 |
| Sohrabi, M | 1 |
| Yoshida, T | 1 |
| Yoshioka, K | 1 |
| Sakane, N | 1 |
| Umekawa, T | 1 |
| Kondo, M | 1 |
2 reviews available for probucol and Liver Steatosis
| Article | Year |
|---|---|
Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review.
Topics: Acetylcysteine; Adult; Alanine Transaminase; Aspartate Aminotransferases; Carnitine; Child; Dietary | 2009 |
Review article: Drug therapy for non-alcoholic fatty liver disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Ascorbic Acid; Betaine; Cholagogues and Chol | 2006 |
3 trials available for probucol and Liver Steatosis
| Article | Year |
|---|---|
Probucol in the treatment of nonalcoholic steatohepatitis: an open-labeled study.
Topics: Adult; Antioxidants; Fatty Liver; Female; Hepatitis; Humans; Liver Function Tests; Male; Middle Aged | 2003 |
Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Double-Blind Met | 2003 |
Liver histology changes in nonalcoholic steatohepatitis after one year of treatment with probucol.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Antioxidants; Aspartate Aminotransferases; Bi | 2008 |
5 other studies available for probucol and Liver Steatosis
| Article | Year |
|---|---|
Effects of probucol on hepatic tumor necrosis factor-alpha, interleukin-6 and adiponectin receptor-2 expression in diabetic rats.
Topics: Animals; Diabetes Mellitus, Experimental; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Interleuki | 2009 |
Pharmacologic therapy of non-alcoholic steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Anti-Obesity Agents; Antioxidants; Betaine; Cholagogues and | 2009 |
Probucol ameliorates the development of nonalcoholic steatohepatitis in rats fed high-fat diets.
Topics: Animals; Anticholesteremic Agents; Dietary Fats; Fatty Liver; Gene Expression Regulation; Lipid Meta | 2013 |
Optimal management of nonalcoholic fatty liver/steatohepatitis.
Topics: Alanine Transaminase; Antioxidants; Fatty Liver; Hepatitis; Humans; Oxidative Stress; Probucol | 2003 |
Probucol prevents the progression of fatty liver in MSG obese mice.
Topics: Animals; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholinesterases; Di | 1995 |